BCG updates its annual review of new drug modalities, tracking how antibodies, recombinant proteins, cell and gene therapies, nucleic acids and radiopharmaceuticals are reshaping biopharma pipelines. Conventional drugs posted their biggest gain since BCG began tracking, pulling the new modality share of projected pipeline value down to 57%, while dealmaking for China originated assets keeps climbing.
New Drug Modalities 2026: Pipeline Value Plateaus
BCG
Lu Chen, Brian Bush
Research
10 Pages
Key Takeaways
Pipeline Value Plateaus: Five year forward pipeline value rose to $347 billion from $330 billion, but new modalities held flat at about $198 billion.
Obesity Forecasts Cooled: Aggregate forecast value for GLP-1 products fell 7% on CagriSema revisions, semaglutide pricing pressure and oral competition, even as product counts rose.
China Drives Dealmaking: China originated assets made up about 50% of top 20 pharma new modality deal value in 2026, up from 40% last year.